Literature DB >> 19593511

Postoperative endocrine therapy for invasive breast cancer.

Leisha A Emens1, Nancy E Davidson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19593511      PMCID： PMC3086398          DOI： 10.1007/978-0-387-75115-3_10

Source DB:  PubMed          Journal:  Cancer Treat Res        ISSN： 0927-3042


× No keyword cloud information.
  75 in total

1.  Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.

Authors:  Alan S Coates; Aparna Keshaviah; Beat Thürlimann; Henning Mouridsen; Louis Mauriac; John F Forbes; Robert Paridaens; Monica Castiglione-Gertsch; Richard D Gelber; Marco Colleoni; István Láng; Lucia Del Mastro; Ian Smith; Jacquie Chirgwin; Jean-Marie Nogaret; Tadeusz Pienkowski; Andrew Wardley; Erik H Jakobsen; Karen N Price; Aron Goldhirsch
Journal:  J Clin Oncol       Date:  2007-01-02       Impact factor: 44.544

2.  Ovarian ablation or suppression in premenopausal early breast cancer: results from the international adjuvant breast cancer ovarian ablation or suppression randomized trial.

Authors: 
Journal:  J Natl Cancer Inst       Date:  2007-04-04       Impact factor: 13.506

3.  Late risk of relapse and mortality among postmenopausal women with estrogen responsive early breast cancer after 5 years of tamoxifen.

Authors:  H F Kennecke; I A Olivotto; C Speers; B Norris; S K Chia; C Bryce; K A Gelmon
Journal:  Ann Oncol       Date:  2006-10-09       Impact factor: 32.976

4.  Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study.

Authors:  Robert E Coleman; Linda M Banks; Samia I Girgis; Lucy S Kilburn; Eduard Vrdoljak; John Fox; Simon J Cawthorn; Ashraf Patel; Claire F Snowdon; Emma Hall; Judith M Bliss; R Charles Coombes
Journal:  Lancet Oncol       Date:  2007-02       Impact factor: 41.316

5.  Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: a meta-analysis.

Authors:  Walter Jonat; Michael Gnant; Francesco Boccardo; Manfred Kaufmann; Alessandra Rubagotti; Ivan Zuna; Mike Greenwood; Raimund Jakesz
Journal:  Lancet Oncol       Date:  2006-12       Impact factor: 41.316

6.  Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial.

Authors:  R C Coombes; L S Kilburn; C F Snowdon; R Paridaens; R E Coleman; S E Jones; J Jassem; C J H Van de Velde; T Delozier; I Alvarez; L Del Mastro; O Ortmann; K Diedrich; A S Coates; E Bajetta; S B Holmberg; D Dodwell; E Mickiewicz; J Andersen; P E Lønning; G Cocconi; J Forbes; M Castiglione; N Stuart; A Stewart; L J Fallowfield; G Bertelli; E Hall; R G Bogle; M Carpentieri; E Colajori; M Subar; E Ireland; J M Bliss
Journal:  Lancet       Date:  2007-02-17       Impact factor: 79.321

7.  Similar efficacy for ovarian ablation compared with cyclophosphamide, methotrexate, and fluorouracil: from a randomized comparison of premenopausal patients with node-positive, hormone receptor-positive breast cancer.

Authors:  Bent Ejlertsen; Henning T Mouridsen; Maj-Britt Jensen; Nils-Olof Bengtsson; Jonas Bergh; Soren Cold; Per Edlund; Marianne Ewertz; Peter W de Graaf; Claus Kamby; Dorte L Nielsen
Journal:  J Clin Oncol       Date:  2006-11-01       Impact factor: 44.544

8.  Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA.17.

Authors:  Paul E Goss; James N Ingle; Silvana Martino; Nicholas J Robert; Hyman B Muss; Martine J Piccart; Monica Castiglione; Dongsheng Tu; Lois E Shepherd; Kathleen I Pritchard; Robert B Livingston; Nancy E Davidson; Larry Norton; Edith A Perez; Jeffrey S Abrams; David A Cameron; Michael J Palmer; Joseph L Pater
Journal:  J Clin Oncol       Date:  2007-04-23       Impact factor: 44.544

9.  Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial.

Authors:  James N Ingle; Dongsheng Tu; Joseph L Pater; Silvana Martino; Nicholas J Robert; Hyman B Muss; Martine J Piccart; Monica Castiglione; Lois E Shepherd; Kathleen I Pritchard; Robert B Livingston; Nancy E Davidson; Larry Norton; Edith A Perez; Jeffrey S Abrams; David A Cameron; Michael J Palmer; Paul E Goss
Journal:  Breast Cancer Res Treat       Date:  2006-03-16       Impact factor: 4.872

10.  Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials.

Authors:  J Cuzick; L Ambroisine; N Davidson; R Jakesz; M Kaufmann; M Regan; R Sainsbury
Journal:  Lancet       Date:  2007-05-19       Impact factor: 79.321
View more
  1 in total

Review 1.  Current Management Strategies in Breast Cancer by Targeting Key Altered Molecular Players.

Authors:  Shazia Ali; Neelima Mondal; Hani Choudhry; Mahmood Rasool; Peter N Pushparaj; Mohammad A Khan; Maryam Mahfooz; Ghufrana A Sami; Jummanah Jarullah; Ashraf Ali; Mohammad S Jamal
Journal:  Front Oncol       Date:  2016-03-01       Impact factor: 6.244
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.